Investors purchased shares of Bristol-Myers Squibb (NYSE:BMY) on weakness during trading hours on Friday. $135.23 million flowed into the stock on the tick-up and $88.81 million flowed out of the stock on the tick-down, for a money net flow of $46.42 million into the stock. Of all equities tracked, Bristol-Myers Squibb had the 12th highest net in-flow for the day. Bristol-Myers Squibb traded down ($0.19) for the day and closed at $58.65
Several equities research analysts recently issued reports on the stock. Jefferies Group set a $66.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Friday. ValuEngine cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, March 7th. Vetr raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating and set a $60.72 target price on the stock in a research report on Thursday, February 1st. Credit Suisse Group set a $62.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Monday, January 22nd. Finally, DZ Bank cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, February 28th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average target price of $66.45.
The stock has a market cap of $98,248.84, a price-to-earnings ratio of 19.49, a P/E/G ratio of 1.56 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.43 and a current ratio of 1.55.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, May 1st. Stockholders of record on Friday, April 6th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, April 5th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.73%. Bristol-Myers Squibb’s payout ratio is currently 53.16%.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Delphi Private Advisors LLC bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth $108,000. Atlantic Trust LLC bought a new stake in shares of Bristol-Myers Squibb in the second quarter worth $111,000. Massey Quick Simon & CO. LLC increased its stake in shares of Bristol-Myers Squibb by 523.5% in the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 1,492 shares during the last quarter. NuWave Investment Management LLC bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth $119,000. Finally, Horan Capital Advisors LLC. bought a new stake in shares of Bristol-Myers Squibb in the third quarter worth $122,000. 71.53% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Traders Buy Bristol-Myers Squibb (BMY) on Weakness” was first published by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://dakotafinancialnews.com/2018/04/13/traders-buy-bristol-myers-squibb-bmy-on-weakness.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.